Senior Medical Advisor · Last reviewed January 2025
Type 2 diabetes is the most prevalent form of diabetes, affecting approximately 34 million Americans. Unlike Type 1, it develops over years through progressive insulin resistance and declining beta-cell function — meaning that intervention at earlier stages of the continuum (prediabetes, insulin resistance) can prevent or delay progression.
Risk Factors and Prevention
The most significant modifiable risk factors for Type 2 diabetes include overweight and obesity (particularly central adiposity), physical inactivity, and diet quality. The landmark Diabetes Prevention Program (DPP) study demonstrated that intensive lifestyle intervention (7% weight loss, 150 minutes per week of moderate physical activity) reduced progression from prediabetes to Type 2 diabetes by 58% over three years — significantly outperforming metformin (31% reduction). The CDC's National DPP program offers evidence-based lifestyle change programs nationwide.
Glycemic Management Goals
The American Diabetes Association's 2024 Standards of Medical Care in Diabetes recommends an HbA1c target of less than 7% for most non-pregnant adults, with individualization based on age, comorbidities, hypoglycemia risk, and patient preferences. Less stringent targets (HbA1c 7.5–8%) may be appropriate for older adults, those with limited life expectancy, or those with a history of severe hypoglycemia.
Lifestyle Management
Medical nutrition therapy, physical activity, and weight management remain foundational components of Type 2 diabetes management at all stages. No single dietary pattern is universally recommended — Mediterranean, low-carbohydrate, and DASH-style approaches have all demonstrated glycemic benefits in trials. 150 minutes per week of moderate-intensity aerobic activity and resistance training are standard recommendations, with demonstrated benefits on HbA1c, cardiovascular risk, and insulin sensitivity.
Pharmacological Treatment
Metformin remains the preferred first-line pharmacological agent for most individuals with Type 2 diabetes due to its efficacy, safety, low cost, and cardiovascular neutrality. For individuals with established cardiovascular disease, heart failure, or chronic kidney disease, SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) and GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) have demonstrated cardiovascular and renal protective benefits beyond glycemic control and are now preferentially recommended in these populations by ADA guidelines.
Related: Diabetes Overview · Diabetes Complications · Diabetes & Mental Health